LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals operates as a biopharmaceutical royalty company that acquires and structures royalty interests in mid- to late-stage development and commercial drug products, generating long-duration cash flows from partner-commercialized medicines.
LIGAND PHARMACEUTICALS INC has a $10.9M market cap.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks LGNZZ's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LGNZZ.
$ curl https://api.spokenalpha.com/v1/companies/LGNZZFAQ
Spoken Alpha indexes LGNZZ's earnings call transcripts at https://spokenalpha.com/companies/LGNZZ. Each call links to attributed speakers and parsed analyst Q&A. LIGAND PHARMACEUTICALS INC's own investor relations page is at https://investor.ligand.com/overview/default.aspx.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.65 | $3.85 | +20.7% | +1.5% | -0.7% |
| Q4 FY2026 | $4.41 | $3.95 | +11.6% | -0.6% | -3.5% |
| Q3 FY2026 | $4.59 | $4.04 | +13.6% | +9.0% | +6.2% |
| Q2 FY2026 | $4.92 | $4.12 | +19.5% | +0.8% | +2.4% |
| Q1 FY2025 | $4.80 | $3.98 | +20.6% | +0.9% | -1.5% |
CFO since 2025 • 2/4 beats (50%) • guidance suspended Q1 FY2026
| Q4 FY2025 |
| $4.65 |
| $3.94 |
| +17.9% |
| -0.9% |
| -0.3% |
| Q3 FY2025 | $4.88 | $4.01 | +21.7% | +8.5% | +8.4% |
| Q2 FY2025 | $4.74 | $4.25 | +11.5% | -2.4% | -2.9% |
| Q1 FY2024 | $4.94 | $4.22 | +17.0% | -1.3% | -0.7% |
| Q4 FY2024 | $4.97 | $4.16 | +19.5% | +6.7% | +5.6% |